Current grant support:
NIH R41 CA81829 (PI) 07/08/02-06/30/05
Title: Adenovirus Replication-Competent Anti-Cancer Vector.
This grant supports the development and characterization of novel adenovirus
replication-competent vectors for potential use in treating human cancer.
Sponsored Research Agreement (PI) 02/01/02-01/31/05
The major goal of this project is to conduct preclinical experiments designed
to conduct a clinical trial for human cancer using an oncolytic adenovirus
cancer gene therapy vector.
NIH R41 CA96364 (PI) 05/09/03-04/30/05
Title: Chaperone-based Tumor Therapy Delivered by Viral Vectors.
This grant supports the development of a vaccinia virus-based vector that
expresses the GRP94 chaperone, and the potential ability of the chaperone
to boost cell-mediated immunity against tumors.
NIH R41 CA105841(Doronin, PI) 04/01/04-03/31/05
Title: Regulatable expression of TRAIL and viral oncolysis.
This grant will support the characterization of adenovirus cancer gene therapy
vectors whose replication is regulatable by tetracyclin and that express TRAIL,
a death ligand in the Tumor Necrosis Factor family that induces apoptosis.
NIH R43 CA108046 (Lichtenstein, PI) 03/01/04-02/28/05
Title: Adenovirus replication-competent anti-cancer vectors that express TRAIL.
This grant will support the characterized killing of cancerous and normal
cells by VRX-013, VRX-014, VRX-015, or VRX-016; and experiments to conduct
subcutaneous and orthotopic tumor model studies with VRX-013, VRX-014, VRX-015,
or VRX-016.
USPHS R01 CI00094 (PI) 09/15/03-09/14/08
Title: Molecular basis of flavivirus neurovirulence.
This grant will define molecular determinants governing replication and neurovirulence
of flaviviruses (yellow fever virus, Japanese Encephaltis Virus) in normal
and immunodeficient mice. The grant will focus on mutations in the E protein
in the neuroadapted yellow fever virus 17D vaccine strain, the highly neurovirulent
French neurotropic yellow fever virus vaccine strain, and the highly neurovirulent
Japanese encephalitis virus Nakayama strain.
NIH R41 CA108335 08/17/04-07/31/05
Title: Animal model for adenovirus oncolytic vectors.
This grant will determine the properties of human adenovirus infection and
E3 and ADP function in Syrian hamster cell lines, and explore the Syrian hamster
as an animal model for the VRX-007 cancer gene therapy vector.